Secretariat office for the 74th Annual Meeting of the Japanese Society of Hematology
c/o Congress Corporation
Kohsai-kaikan Bldg., 5-1 Kojimachi, Chiyoda-ku, Tokyo 102-8481
Tel:+81-3-5216-5318
Fax:+81-3-5216-5552
E-mail:jsh2012@congre.co.jp
[ 11:15~12:00 ] | [ Main Hall ] |
Chairperson: Keiya Ozawa (Jichi Medical University, Japan)
|
|
Speaker: Neal S. Young (NHBLI, NIH, USA)
|
[ 11:15~12:00 ] | [ Annex 1 ] |
Chairperson: Tomoki Naoe (Nagoya University, Japan)
|
|
Speaker: Ulrich Jäger (Medical University of Vienna (MUW), Austria)
|
[ 13:50~16:00 ] | [ Main Hall ] |
Chairpersons:
Keiya Ozawa (Jichi Medical University, Japan)
Renier J. Brentjens (Memorial Sloan Kettering Cancer Center, USA) |
|
Speakers:
|
|
Chimeric antigen receptor (CAR) modified T cells as a novel approach to cancer immunotherapy: Initial promising clinical responses and future directions | |
Renier J. Brentjens (Memorial Sloan Kettering Cancer Center, USA)
|
|
Gene therapy for hemophilia | |
Katherine A. High
(Perelman School of Medicine at the University of Pennsylvania/Howard Hughes Medical Institute/The Children's Hospital of Philadelphia, USA) |
|
Genome editing with engineered zinc finger nucleases | |
Philip D. Gregory (Sangamo BioSciences Inc, USA)
|
|
iPS cell research using large animals | |
Yutaka Hanazono (Jichi Medical University, Japan)
|
[ 9:00~11:10 ] | [ Annex 2 ] |
Chairpersons:
Tsukasa Ohmori (Jichi Medical University, Japan)
Yutaka Yatomi (The University of Tokyo, Japan) |
|
Speakers:
|
|
Pathophysiology and diagnosis of primary immune thrombocytopenia | |
Yoshiaki Tomiyama (Osaka University Hospital, Japan)
|
|
Current management of immune thrombocytopenia in Japan | |
Yoshitaka Miyakawa (Keio University, Japan)
|
|
Thrombopoietin mimetics for the treatment of ITP | |
David J. Kuter (Harvard Medical School, USA)
|
|
Chronic immune thrombocytopenia as a disease with or without association of defined diseases in children | |
Masatoshi Takagi (Tokyo Medical and Dental University, Japan)
|
|
Thrombocytopenia in the antiphospholipid syndrome | |
Ricard Cervera (Department of Autoimmune Diseases, Hospital Clinic, Spain)
|
[ 9:00~11:10 ] | [ Room A ] |
Chairpersons:
Toru Nakano (Osaka University, Japan)
Toshikazu Ushijima (National Cancer Center, Japan) |
|
Speakers:
|
|
Role of the polycomb group proteins in the restriction of tumor development | |
Atsushi Iwama (Chiba University, Japan)
|
|
H3K27 methylation regulators and their roles in acute leukemia | |
Iannis Aifantis (NYU School of Medicine, Howard Hughes Medical Institute, USA)
|
|
Regulation of histone modifications in hematopoietic and leukemic stem cells | |
Issei Kitabayashi (National Cancer Center Research Institute, Japan)
|
|
Aberrant DNA methylation - Its origin and diagnostic applications | |
Toshikazu Ushijima (National Cancer Center, Japan)
|
|
Cancer epigenetics: New drugs and paradigms | |
Frank Lyko (German Cancer Research Center, Germany)
|
[ 13:50~16:00 ] | [ Room A ] |
Chairpersons:
Hitoshi Kiyoi (Nagoya University, Japan)
Kazuo Tamura (Fukuoka University, Japan) |
|
Speakers:
|
|
Cancer stem cell research for innovative Cell-modifying technologies | |
Hideshi Ishii (Osaka University, Japan)
|
|
DNA hydroxymethylation in hematologic malignancies | |
Mamiko Sakata -Yanagimoto (University of Tsukuba, Japan)
|
|
Novel molecularly targeted therapy targeting resistant signals | |
Seiji Yano (Kanazawa University, Japan)
|
|
Prognostic, predictive and therapeutic role of microRNAs in AML | |
Guido Marcucci
(The Ohio State University Medical Center, Comprehensive Cancer Center, USA) |
|
Role of molecular diagnostics and MRD to guide therapy in AML | |
Farhad Ravandi-Kashani (University of Texas-MD Anderson Cancer Center, USA)
|
[ 10:40~11:10 ] | [ Annex 1 ] |
Chairperson:
Shigetaka Asano
(Waseda University, Japan / Professor Emeritus, The University of Tokyo, Japan) |
|
Speaker: Robert Peter Gale (Imperial College, UK)
|
[ 11:15~12:00 ] | [ Annex 1 ] |
Chairperson: Toshio Suda (Keio University, Japan)
|
|
Speaker: Armand Keating (Princess Margaret Hospital / The University of Toronto, Canada)
|
[ 9:00~11:10 ] | [ Annex 1 ] |
Chairpersons: Hideki Nakakuma (Wakayama Medical University, Japan)
Mario Cazzola (University of Pavia, Italy) |
|
Speakers:
|
|
Preferential activation of hematopoietic stem cells with genetic alterations in patients with acquired aplastic anemia | |
Shinji Nakao (Kanazawa University, Japan)
|
|
The molecular basis of myelodysplastic syndromes and its clinical relevance | |
Mario Cazzola (University of Pavia, Italy)
|
|
Similarities and differences between hypoplastic refractory cytopenia and aplastic anemia in children | |
Seiji Kojima (Nagoya University, Japan)
|
|
The pathophysiology of PNH: Lessons from targeted therapy | |
Peter Hillmen (St. James's Institute of Oncology, UK)
|
[ 9:00~11:10 ] | [ Room A ] |
Chairpersons:
Taira Maekawa (Kyoto University, Japan)
Tomohiro Morio (Tokyo Medical and Dental University, Japan) |
|
Speakers:
|
|
Clinical development of MSC for the treatment of steroid refractory acute GVHD in Japan | |
Katsuhiko Tachibana (JCR Pharmaceuticals Co., Ltd., Japan)
|
|
Mesenchymal stem cells for treatment of Graft-Versus-Host Disease | |
Katarina Le Blanc (Laboratory Medicine, Herm, Karolinska Institutet, Swden)
|
|
Regulation of hematopoiesis by mesenchymal stem cells | |
Yasuo Miura (Kyoto University Hospital, Japan)
|
|
Mesenchymal stem cells expand the spectrum of cell therapy | |
Edwin M. Horwitz (The University of Pennsylvania Perelman School of Medicine, USA)
|
|
Mesenchymal stem cell-based therapy -bench to bed- | |
Akihiro Umezawa (National Center for Child Health and Development, Japan)
|
[ 14:45~16:55 ] | [ Main Hall ] |
Chairpersons: Wyndham Wilson (National Cancer Institute, USA)
Kensei Tobinai (National Cancer Center Hospital, Japan) |
|
Speakers:
|
|
Molecular pathogenesis of B-cell lymphoma | |
Riccardo Dalla-Favera (Columbia University, USA)
|
|
Molecular characterization of T/NK cell malignancies | |
Masao Seto (Aichi Cancer Center Research Institute, Japan)
|
|
Diffuse large B-cell lymphoma: Treatment decisions based on molecular features | |
Wyndham Wilson (National Cancer Institute, USA)
|
|
Science-based management of adult T-cell leukemia-lymphoma | |
Kunihiro Tsukasaki (Nagasaki University Hospital, Japan)
|
[ 14:45~15:15 ] | [ Annex 2 ] |
Chairperson: Hiroshi Shiku (Mie University, Japan)
|
|
Speaker: Frank Marini
(Wake Forest Institute for Regenerative Medicine, Wake Forest Comprehensive Cancer Center, USA) |
[ 15:15~15:45 ] | [ Annex 2 ] |
Chairperson: Kenzaburo Tani (Medical Institute of Bioregulation, Kyushu University, Japan)
|
|
Speaker: Fabio Candotti (Bethesda, MD, USA)
|
[ 9:00~11:10 ] | [ Room D ] |
Chairpersons: Kaiyan Liu (Peking University People's Hospital, China)
Shigeru Chiba (Tsukuba University, Japan) |
|
Speakers:
|
|
Prognostic relevance of recurrent mutations in adult acute myeloid leukemia | |
Chirayu Udomsakdi Auewarakul (Mahidol University, Thailand)
|
|
A mouse model bearing "conventional" knock-in of Npm1 mutation reveals myeloid expansion and implies a perturbation in hematopoietic microenvironment | |
Wen-Chien Chou (National Taiwan University Hospital and Fu-Jen University, Taiwan)
|
|
Targeting chemotherapy-resistant AML stem cells | |
Fumihiko Ishikawa (RIKEN Research Center for Allergy and Immunology, Japan)
|
|
Immunotherapy utilizing haploidentical HCT and subsequent donor NK cell infusion in refractory acute leukemia | |
Kyoo-Hyung Lee
(University of Ulsan, Asan Medical Center, Korea) |
|
Allogeneic hematopoietic stem cell transplantation in China: Where we are and where to go | |
Xiao-jun Huang (Peking University People's Hospital, China)
|
[ 9:00~11:10 ] | [ Main Hall ] |
Chairpersons: Masahiro Kizaki (Saitama Medical Center, Saitama Medical University, Japan)
Shinsuke Iida (Nagoya City University, Japan) |
|
Speakers:
|
|
Origin of the myeloma initiating cells and development of its targeting therapies | |
Naoki Hosen (Osaka University, Japan)
|
|
Intracellular targets of Immunomodulatory derivatives of thalidomide (IMiD®) | |
Suzanne Lentzsch (Columbia University, USA)
|
|
How to overcome the cell adhesion-mediated drug resistance in multiple myeloma | |
Yusuke Furukawa (Jichi Medical University, Japan)
|
|
Targeting the interplay between myeloma cells and the bone marrow microenvironment | |
Masahiro Abe (University of Tokushima, Japan)
|
|
Targeting myeloma cells and their marrow microenvironment | |
Kenneth C. Anderson
(Jerome Lipper Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, USA) |